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Abstract
Background: Hepatitis C (HCV) and human immunodeficiency virus (HIV) infections are a major burden to public
health worldwide. Routine antenatal HIV-1 screening to prevent maternal-infant transmission is universally
recommended. Our objectives were to evaluate the prevalence of and potential risk factors for HCV and HIV infection
among pregnant women who attended prenatal care under the coverage of public health in Central Brazil.
Methods: Screening and counselling for HIV and HCV infections was offered free of charge to all pregnant women
attending antenatal clinic (ANC) in the public health system, in Goiania city (~1.1 million inhabitants) during 2004–2005.
Initial screening was performed on a dried blood spot collected onto standard filter paper; positive or indeterminate
results were confirmed by a second blood sample. HCV infection was defined as a positive or indeterminate sample (EIA
test) and confirmed HCV-RNA technique. HIV infection was defined according to standard criteria. Factors associated
with HIV and HCV infections were identified with logistic regression. The number needed to screen (NNS) to prevent
one case of infant HIV infection was calculated using the Monte Carlo simulation method.
Results: A total of 28,561 pregnant women were screened for HCV and HIV-1 in ANC. Mean maternal age was 23.9
years (SD = 5.6), with 45% of the women experiencing their first pregnancy. Prevalence of HCV infection was 0.15% (95%
CI 0.11%–0.20%), and the risk increased with age (p < 0.01). The prevalence of anti-HIV infection was 0.09% (95% CI
0.06%–0.14%). Black women had a 4.9-fold (95% CI 1.42–16.95) greater risk of HIV-1 infection compared to non-black
women. NNS to prevent one case of infant HIV infection ranged from 4,141 to 13,928.
Conclusion: The prevalence of HIV and HCV infections were low among pregnant women, with high acceptability rates
in the opt-in strategy in primary care. Older maternal age was a risk factor for HCV and antenatal HCV testing does not
fulfill the requirements for screening recommendation. The finding of higher risk of HIV-1 infection among black women
despite being in consonance with the HIV-1 ethnic pattern in some American regions cannot be ruled out to be a
surrogate marker of socio-economic condition.
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Background
Hepatitis C virus and HIV infections are a major burden to
public health worldwide and share common blood-borne
transmission routes. Approximately 130 million individ-
uals are HCV-infected, with 3.4 million newly infected
cases per year, representing a leading cause of liver cancer
and transplant worldwide [1]. HIV infection affects
around 33 million individuals, with an increasing trend
among women that results in mother-to child transmis-
sion being the major route for HIV infection in children
[2,3]. Among HIV-infected individuals, four to five mil-
lion are estimated to be co-infected with HCV [1].
Routine antenatal HCV screening to prevent vertical trans-
mission is a controversial issue and is not universally
implemented. Although HCV infection is considered an
important public health problem for which reliable
screening tests exist, treatment is contra-indicated during
pregnancy due to the potential risks of the diagnostic pro-
cedure [4-7]. In general, antenatal and population screen-
ing is recommended for those possessing a risk factor for
HCV acquisition, such as intravenous drug users, recipi-
ents of blood transfusions or organs before 1990, haemo-
dialysis patients and HIV-infected individuals [8,9]. In
Brazil, universal screening is mandatory for blood donors.
A few population-based studies have reported anti-HCV
prevalence varying from 1.2% to 1.9% [10-13], and the
vast majority of studies were restricted to high risk groups
in selective areas.
Antenatal HIV screening is universally recommended to
prevent vertical transmission [14,15]. The mother-to-
child transmission rate varies from 15% to 25% without
preventive measures, but this rate can be substantially
decreased to 2% or less with the adoption of an evidence-
based group of interventions based upon the use of
antiretroviral drugs, the avoidance of breastfeeding and
elective caesarean section [2,16-18]. However, by 2005,
only 11% of HIV-positive pregnant women had gained
access to preventive interventions worldwide [19].
After almost three decades of the AIDS epidemic in Brazil,
an estimated 620 thousand individuals are living with
HIV/AIDS. The prevalence of infection remained stable
over the past years, but the increased heterosexual trans-
mission led to a decline of the male-to-female ratio, which
reached 1.5 to 1 in 2002 [20,21]. Approximately 90% of
the AIDS cases among children (<13 years old) are attrib-
utable to mother-to-child-transmission (MTCT).
Although the rate of vertical transmission has been declin-
ing, the implementation of antenatal HIV screening and
timely management of infected pregnant women varies
across the country due to disparities of health care access,
suggesting missed opportunities for prevention [22-24].
In the current manuscript, we present the prevalence of
HCV and HIV infection among pregnant women attend-
ing an official program (named Mother's Testing)
launched in 2004 that aims to extend the coverage of ante-
natal screening in public health settings in Central Brazil.
This study also analyses potential risk factors for acquisi-
tion of these infections associated with maternal charac-
teristics, focusing on the discussion of timely strategies
and the estimated outcomes of this screening program.
Methods
Study Design, Population and Recruitment
A cross-sectional study was conducted among pregnant
women who attended prenatal clinics located in Goiania,
a city of ~1.1 million inhabitants in Central Brazil,
between 2004 and 2005. Since 2004, screening for nine
infectious diseases (including HIV and HCV) has been
offered free of charge by an extended Women's Prevention
Program sponsored by the State Secretariat of Health (Pro-
grama de Protecao a Gestante). This screening program
covers all pregnant women who attend the 243 public
health centres, which corresponds to 60% of the esti-
mated number of pregnant women in this region. In
1997, the policy of universal screening for HIV and coun-
selling for pregnant women was adopted by the Brazilian
Ministry of Health. HCV testing is not part of the routine
antenatal screening for vertical transmission prevention.
Data collection
During the first prenatal visit, a standardized question-
naire is filled in by the health technicians. At the time of
blood collection, the following variables are recorded:
clinic of attendance; date of maternal birth; last menses;
gestational age (weeks); parity; type of previous delivery;
number of abortions. Enclosed in the questionnaire was a
consent form; informed consent was obtained for HIV-1
and HCV testing as an "opt in" procedure.
Specimen collection and serological tests
At the first screening, blood samples were collected by dig-
ital puncture onto standard filter paper (S&S 903), dried
at room temperature (~4 hours) and sent daily by special
mail to the Central Reference Laboratory. For confirma-
tory tests, a second blood venous puncture (vaccutainer)
was collected for all pregnant women with positive and
indeterminate results in the serological screening using fil-
ter paper eluate.
HCV screening and confirmatory tests
HCV screening was based on the detection of antibodies
against HCV core, NS3, NS4 and NS5 antigens (DETECT®
commercial kit ADALTIS INC., Canada). As part of the
confirmatory procedure the second serum sample
obtained from venous puncture was retested by another
ELISA kit (Hepanostika HCV Ultra Beijing United Bio-
medical Co. Ltd., China). In parallel, detection of HCV-
RNA was obtained by qualitative AMPLICOR HCV Test
(Roche, USA). Samples positive or indeterminate to ELISABMC Infectious Diseases 2009, 9:116 http://www.biomedcentral.com/1471-2334/9/116
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and confirmed by HCV-RNA were considered HCV
infected.
HIV screening and confirmatory tests
Serological screening for HIV1/2 in filter paper used an
anti-HIV TETRA ELISA commercial kit (Biotest, Germany)
to detect anti-HIV1 antibodies (gp41, gp36 and p24) and
anti-HIV2 antibodies with sensitivity of 100.0% and spe-
cificity of 99.8%, according to the manufacturer. Screened
women with positive and indeterminate results were re-
tested using sera from venous puncture blood samples
(GENSCREEN® HIV1/2 kit Bio-Rad, France) that recog-
nizes antibodies against antigens gp160 and gp25 or by
HIV-1/2 ELISA test (Wiener lab., Argentina) that detects
antibodies against the pop and gag regions' antigens.
In parallel, at least one of the following confirmatory tests
were applied: Indirect Immunofluorecence by IFI – HIV1
kit (Bio-Manguinhos, Fundação Oswaldo Cruz, Rio de
Janeiro); Immuno Blot (IB) using a NEW LAV BLOT 1 kit
(Bio-Rad, France) that detects antibodies against HIV-1
gp160, gp110/120, p68, p55, p52, gp41, p40, p34, p24/
25 and p18; Western Blot (WB) for detection of HIV1 and
HIV2, using HIV BLOT 2.2 kit (Genelabs ® Diagnostics Pte
Ltd, Singapore) and qualitative "Nested" PCR to detect
pro viral HIV1 DNA in blood mononuclear cells (50 cop-
ies/mL detection limit), performed at the Center of
Genomics Laboratory (São Paulo, Brazil).
A pregnant woman was considered to be HIV-infected if
the initial positive and indeterminate screening test was
confirmed by anti-HIV1/2 ELISA in a second serum sam-
ple combined with a positive result obtained in any other
technique (IFI, IB, WB or PCR), as recommended by the
Brazilian Ministry of Health [25].
Data analysis
Data were analyzed by using the chi-square test with Yates'
correction for univariate analysis. Prevalence estimates of
HCV and HIV infections were reported with 95 percent
confidence intervals (95% CI). Outcome measures were
HCV and HIV infections. The variables age-group, race/
ethnicity, number of pregnancies, mode of delivery and
gestational age were evaluated by measuring the strength
of association with the outcomes by odds ratios (OR) and
their respective 95% CI. Multivariate analysis was con-
ducted by using logistic regression, with anti-HCV and
HIV serologic results as the dependent variable (SPSS,
Inc., Chicago, Illinois). All variables found to be associ-
ated with HCV or HIV infection then were evaluated in a
final model, controlling for age.
The Number Needed to Screen (NNS) to prevent one case
of mother to child transmission of HIV was calculated
using the following parameters: prevalence of HIV infec-
tion obtained by the current study; sensitivity of the test
(0.99); number receiving test results; number of cases of
mother to child transmission expected without interven-
tions among women receiving test results; number receiv-
ing combination antiretroviral therapy; number receiving
elective cesarean section (C-section) [15,26]. We used the
Monte Carlo simulation method to calculate the NNS
considering antiretroviral therapy and elective C- section.
Briefly, the simulation model uses the above parameters
and generates relative risks (RRs) by the combination of
preventive measures (combination of antiretroviral regi-
mens and elective cesarean) to avoid vertical transmis-
sion. The underlying assumption was the normal
distribution of log (RR) and these values transformed
back to the original scale were used to estimate NNS and
95% CI based on 1 000 000 samples. The R software was
used for the calculations and the written program to per-
form simulation was kindly provided by Chou et al, 2005.
The large sample size (n = 28,561 pregnant women) of the
study is sufficient to produce quite narrow 95% confi-
dence intervals even considering small numbers for prev-
alence estimates of HCV and HIV infections.
Ethical issues
Both HIV and HCV tests are offered as part of the routine
panel tests in this antenatal screening public health pro-
gram as an opt-in strategy which require explicit written
consent and pretest counseling. The State Public Health
Program (Programa de Proteção à Gestante/PPG-Go)
ensures the release of test results and medical counselling
free of charge and also monitors maternal-child out-
comes.
Results
During the study period, a total of 28,561 pregnant
women were screened for HCV and HIV infections in pre-
natal public health clinics. Only 15 out of 28,576 partici-
pants (0.05%) refused to sign the informed consent for
HIV and HCV tests. Approximately 85% of the women
enrolled were under 30 years of age (mean = 23.9; sd =
5.6), 0.8% were between 12 to 14 years old and approxi-
mately 1% were older than 40 years. More than 90% of
the study population self-referred as white or mixed/bira-
cial, with 8.3% black and a minority of Asian descendents
and indigenous individuals (Table 1).
The maternal characteristics and delivery history are pre-
sented in Table 1. Approximately half of the women were
experiencing their first pregnancy, and 11% reported four
or more pregnancies. For those with a previous history of
pregnancies, around 55% reported vaginal delivery and
around 30% reported caesarean sections (with or without
previous abortions). One third of the women reported
having at least one abortion. For the majority of the
attendees (95.5%) the first prenatal medical visit, which
included the first screening test, occurred before the 27thBMC Infectious Diseases 2009, 9:116 http://www.biomedcentral.com/1471-2334/9/116
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gestational week and 60% were screened before the 14th
week (mean = 13.5; sd = 6.3).
The prevalence of anti-HCV antibodies was 0.22% at the
first screening using filter paper eluate. Five out of 65 anti
HCV positive or indeterminate women were not re-tested
because they changed address and could not be traced. Of
the anti-HCV positive women, 92.3% were re-tested for
HCV RNA and of these, 72% (43/60) had detectable
viremia. The percentage of false-positive results was
28.3% (17/60), and the majority of indeterminate results
on the serological screening were not confirmed by
molecular test. The prevalence of HCV infection was
0.15% (95% CI 0.11% – 0.20%) at the prenatal public
health services (Figure 1).
The prevalence of antibodies to HIV-1 was 0.13% at the
initial screening, and 86.8% of the positive participants
were re-tested (33/38). Five out of 38 positive or indeter-
minate women were not re-tested because they changed
address and could not be traced. The percent of false pos-
itive results was 18.2% (6/33), and all indeterminate
results onto filter paper eluate were negative at confirma-
tory tests. The prevalence of HIV infection was 0.09%
(95% CI 0.06%–0.14%) which represents nine infected
pregnant women among 10,000 screened (Figure 1).
Among HIV-1 positive pregnant women, 34.6% had a his-
tory of previous abortion. Two women were HCV-HIV-1
co-infected, resulting in an estimate of seven (95% CI 2–
56) co-infected cases per 100,000 screened women.
Among HIV-1 infected women, the prevalence of HCV
infection was 7.4% (2/27) (data not shown).
In the univariate analysis, there was an increasing trend of
HCV infection among older age-groups (χ2 = 14.6; df = 1;
p < 0.01). Also an increasing number of pregnancies were
positively associated with HCV infection (Table 1).
Higher risk of HCV infection was detected among women
older than 39 years (ORadjusted = 20.40; 95% CI 4.90–
83.33) in the multivariate model. Four or more pregnan-
cies did not remain statistically significant associated
when compared to the first pregnancy (ORadjusted = 1.64;
95% CI 0.68–3.97) after adjusting for age (Table 2).
In univariate analysis, HIV-1 infection was associated with
increasing age up to 39 years old and with women self-
Table 1: Maternal characteristics, prevalence and risk factors for HCV and HIV infection among pregnant women in Public Health 
Settings, Central Brazil
HCV HIV-1
Characteristics Total
N
Positive (%) OR (95% CI) Positive (%) OR (95% CI)
Age, yearsa
12–19 6664 4 (0.06) 1 2 (0.03) 1
20–29 17084 23 (0.13) 2.2 (0.8 – 6.5) 16 (0.09) 3.1 (0.7 – 13.6)
30–39 4272 9 (0.21) 3.5 (1.1–11.4) 7 (0.16) 5.1 (1.1 – 24.8)
≥ 40 268 4 (1.50) 24.9 (6.2–98.9)
Ethnicityb
White 7710 11 (0.14) 1 5 (0.06) 1
Biracial 9523 20 (0.21) 1.5 (0.7 – 3.3) 10 (0.11) 1.6 (0.6 – 4.7)
Black 1576 1 (0.06) 0.4 (0.02 – 3.3) 6 (0.38) 5.9 (1.8 – 19.2)
Asian/indigenous 176
Number of pregnanciesc
First 11637 12 (0.10) 1 9 (0.08) 1
2–3 11079 19 (0.17) 1.7 (0.8 – 3.4) 11 (0.10) 1.3 (0.5 – 3.1)
≥ 4 2780 10 (0.36) 3.5 (1.5 – 8.1) 5 (0.18) 2.3 (0.8 – 6.9)
Previous mode of deliveryd
Vaginal 7665 14 (0.18) 1 5 (0.07) 1
Cesarean section 4301 13 (0.30) 2.0 (0.9 – 4.6) 7 (0.16) 2.5 (0.7 – 9.0)
Abortions only 1893 2 (0.11) 0.6 (0.1 – 2.6) 4 (0.21) 3.2 (0.9 – 12.0)
Gestational age, weekse
< 14 14647 19 (0.13) 1 11 (0.08) 1
14–27 8741 16 (0.18) 0.8 (0.4 – 1.6) 8 (0.09) 1.3 (0.5 – 3.3)
≥ 28 1077 2 (0.19) 1.1 (0.2 – 4.5)
Missing data: a 273; b 9576; c 3065; d 3065; e 4096BMC Infectious Diseases 2009, 9:116 http://www.biomedcentral.com/1471-2334/9/116
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referred as black. Other maternal characteristics were not
related to HIV-1 infection. In the multivariate analysis,
black women had an approximately four-fold greater risk
of being infected compared to white subjects, independ-
ent of age (ORadjusted = 4.90; 95% CI 1.42–16.95). Higher
risk of HIV-1 infection was also detected among women
older than 29 years (ORadjusted = 5.38; 95% CI 1.12–25.64)
in multivariate analysis (Table 2).
The outcomes of the HIV-1 screening and the Number
Needed to Screen (NNS) were calculated for 0.09% HIV-1
prevalence (Table 3). Numbers needed to screen to pre-
vent 1 case of mother to child HIV transmission was esti-
mated as 4,542 (95% CI; 4,141–5,346) if the
combination of antiviral therapy and C-section were 90%
and 50%, respectively. NNS was 11,800 (95% CI 10,730–
13,928) if the combination of antiviral therapy and C-sec-
tion were 60% and 37%, respectively. These were the
wider range of possibilities for the parameters.
Discussion
In the present study, among 28,561 pregnant women who
attended a prenatal screening program, the prevalence of
0.15% for HCV infection was similar to the prevalence of
0.09% for HIV-1 infection. The first prenatal screening
was mainly performed by the second gestational trimester
among young pregnant women. Increasing age was a risk
factor for both HCV and HIV-1 infection, and women self-
referred as black were at greater risk for HIV-1 infection.
This ethnic pattern is in agreement with the recent epide-
miology of HIV-1 infection in pregnant women in Brazil
[27].
The overall prevalence of HCV infection among pregnant
women of 0.15% in our region is comparable to the fig-
ures reported in a similar antenatal program implemented
in the neighbouring State in the Centralwest of Brazil
[28]. Screening of pregnant women conducted in other
Brazilian regions indicated higher HCV frequencies, vary-
ing from 1.0% to 2.6% according to the characteristics
Screening for HCV and HIV infection among pregnant women in Public Health Settings, Central Brazil Figure 1
Screening for HCV and HIV infection among pregnant women in Public Health Settings, Central Brazil. Five 
out of 65 anti HCV-positive/indeterminate women and five out of 38 anti-HIV positive/indeterminate women could not be 
traced for confirmatory test. Doted lines indicate that indeterminate test results (HCV and HIV) were considered negative.
First screening
Confirmatory tests
28,561 pregnant women
47 HCV
Positive
35 HIV 
Indeterminate
18 HCV 3 HIV  28,511 HCV 28,523 HIV 
Negative
28,528 HCV 28,529 HIV 
Prevalence
0.09%
43 HCV 27 HIV 
Positive
17 HCV 6 HIV 
Negative
0.15%BMC Infectious Diseases 2009, 9:116 http://www.biomedcentral.com/1471-2334/9/116
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and risk factors of the population [29-31]. In general, the
prevalence of HCV infection is lower among pregnant
women compared to the general population [11,12] as
shown in our results, since women of childbearing age are
usually less than 40 years old. Older age is a known risk
factor for HCV infection due to the long period of viral
exposure during lifetime. In our study among pregnant
women, HCV infection peaked after 40 years of age, which
was similar to the most affected age-group reported in a
population survey in the US [32].
Around 70% of the suspected cases were confirmed by
HCV RNA by PCR, a marker of active viral replication [33]
that is compatible with previous reports [11,34,35]. In our
study, 15 pregnant women (95% CI 8–25) of 10,000
screened had detectable viremia. This value represents 6 to
13 acquired HCV infections in childhood per year based
on the prevalence obtained among the estimated 90 thou-
sand pregnant women in this State (official data) and the
rates of mother-to-child transmission of 5% to 8%
[36,37]. Genotype 1a (70%) was predominant in our
study and is the most frequent circulating genotype in Bra-
zil [38,39].
Routine antenatal HCV screening, although implemented
in this Public Health Screening Program for pregnant
women (Goiás State), is not mandatory in Brazil, a policy
that is in agreement with the current international guide-
lines [5,40]. In the general population, the screening for
HCV is restricted to high risk groups and is not recom-
mended for asymptomatic adults who are not at increased
risk [40]. However, if the screening was restricted to high
risk group pregnant women, only 40% of those with HCV
infection would be identified [41,42]. In Japan, since
2003, HCV screening for the general population and high
risk groups, targeting those over 40 years old, was imple-
mented and considered to be cost-effective in comparison
to a non-screening strategy [43]. The results of our study
indicates that HCV is associated with older age and not
associated with ethnicity or increasing number of preg-
nancies. In this context, the cost-effectiveness of HCV
screening in older (>40) populations appears to be an
area that presents important opportunities for future
investigation. Currently, no intervention can be offered to
HCV-infected pregnant women to reduce mother-to-
child-transmission [5]. Therefore, HCV antenatal screen-
ing does not appear to have benefits that outweigh the risk
which contrasts with the screening policy for HIV-1 in
pregnant women [44].
The prevalence of HIV-1 infection detected among preg-
nant women in our setting (0.09%) was similar to the
prevalence of HIV-1 infection among women in some
developed European and American countries [45]. In Bra-
Table 2: Adjusted association between risk factors and Hepatitis 
C or HIV-1 infection among pregnant women in Public Health 
Settings, Central Brazil
Variables HCV positive
ORadjusted (95% CI)a
HIV-1 positive
ORadjusted (95% CI)a
Age, years
12–19 1 1
20–29 1.94 (0.66 – 5.75) 3.09 (0.71 – 13.51)
30–39 2.86 (0.84–9.61) 5.38 (1.12 – 25.64)
≥ 40 20.40 (4.90–83.33)
Ethnicity
White 1
Biracial 1.45 (0.49 – 4.32)
Black 4.90 (1.42 – 16.95)
Number of pregnancies
First 1
2–3 1.60 (0.72 – 3.52)
≥ 4 1.64 (0.68 – 3.97)
a Adjusted odds ratio and 95% confidence interval = ORadjusted (95% 
CI)
Table 3: Outcomes of screening for HIV infection in 10,000 pregnant women
Variables Prevalence 0.09%
Women screened, n 10 000
Women identified as HIV-1 positive 9
Women receiving test results 8.1 (91%)a
Women receiving antiretroviral therapy (ARV) 4.9 – 7.4 (60% – 90%)a
Women submitted to elective cesarean 3.0 – 4.1 (37% – 50%)a
Cases of mother-to-child transmission (MCT) expected among women without intervention 1.14 – 2.04 (14% – 25%)a
Number of cases of mother-to-child transmission prevented with ARV 0.59 (95% CI 0.49–0.64)b
1.59 (95% CI 1.32–1.71)b
Number needed to screen (NNS) to prevent one case of infant HIV infection 4,542 (95% CI 4,141–5,346)c
11,800 (95% CI 10,730–13,928)d
MCT = Mother-to-Child Transmission
ARV = Antiretroviral Therapy
a values in parenthesis are from literature sources
b values obtained from the model
c NNS calculated from the combination of preventive measures: ARV (90% and cesarean section (50%)
d NNS calculated from the combination of preventive measures: ARV (60% and cesarean section (37%)BMC Infectious Diseases 2009, 9:116 http://www.biomedcentral.com/1471-2334/9/116
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zil, surveillance data from public hospitals showed
around 0.4% HIV-1 prevalence among a representative
sample of labouring women between 15 to 40 years old,
with regional disparity [46]. We estimated that 4,141 to
13,928 pregnant women need to be screened to prevent
one case of HIV vertical transmission (NNS). We esti-
mated that this screening program could enable the pre-
vention of five to fourteen HIV mother-to child
transmissions per year if the well-established intervention
measures were applied, pointing out the importance of
early screening during the gestational period. These fig-
ures reflect the HIV- 1 prevalence rate in our region, and it
has been found that, in areas with ~50% prevalence such
as Sub-Saharan Africa, NNS is 113 to 304 pregnant
women [15].
In the 1990s, the HIV-1 vertical transmission rate was esti-
mated as 16% in the southeast of Brazil [47], with a reduc-
tion to 7.1% reported in a multicentre study by the year
2001 [22]. Despite the progress in the implementation of
screening and free prophylactic measures in recent years
in Brazil [20,48], it was estimated that approximately 60%
of pregnant women had effective coverage for HIV-1
screening and ~35% of HIV/AIDS positive pregnant
women had access to antiretroviral therapy (ARV), with
differences among regions [46]. In our setting, the strategy
adopted to sign for testing (opt-in) in the antenatal
screening program was well-accepted, with minimal
refusal rates (0.05%). Besides, the use of dried blood spots
on filter paper, as performed by this program, enhances
the coverage of the screening by the simplicity of the
blood collection/storage and mailing procedure, reducing
costs and improving the feasibility of this program [49].
Other large scale screening for infectious disease among
neonates and pregnant women have also used dried
blood spots [28,49], which have been validated with good
correlation with conventional serological tests [50]. In our
study, the initial HIV-1 screening was conducted among
60% of women before 14 weeks of gestation, 95% of the
testing was performed before 27 weeks, and the final diag-
nosis was returned within two weeks, timely for the
implementation of preventive measures.
Our analysis pointed out that women who self-referred as
black had almost 5 fold increase in HIV infection com-
pared to white women in agreement with the Brazilian
official surveillance data [20]. This finding is also in con-
cordance with recent analysis from US population show-
ing that black women had nearly 18 times higher
prevalence than white women based on CDC estimates in
the year 2006 [51]. But we cannot exclude that race/eth-
nicity may be a surrogate marker of socio-economic con-
dition and differential access to health services as
suggested by other studies [46,52]. Other potential risk
factors for HIV infection such as early onset of sexual
activity, high number of sex partners and having sex with
older men were reported among pregnant women [53]
and in the general population [20]. One limitation of our
study was the inability to assemble data on known risk
factors related to sexual behaviour and drug abuse. This
program is intended to cover a large population, and it
would be unfeasible to collect information about sensi-
tive issues like these in public health settings [54].
The prevalence of HIV-HCV co-infection among pregnant
women was low (7 per 100,000); however, among the
HIV-1 infected subgroup, 7% were HCV-infected. This fre-
quency of prevalence of HCV infection among HIV-
infected individuals is similar to the value reported by the
HIV Testing Center regionally [55] and in line with the
current recommendations to screen HIV/AIDS patients for
HCV virus due to the viruses' common route of transmis-
sion and their clinical and therapeutic interactions
[56,57].
Conclusion
The prevalence of HIV and HCV infections were low
among pregnant women, with high acceptability rates in
the opt-in strategy in primary care. Older maternal age
was a risk factor for HCV and antenatal HCV testing does
not fulfill the requirements for screening recommenda-
tion. The finding of higher risk of HIV-1 infection among
black women despite being in consonance with the HIV-
1 ethnic pattern in some American regions cannot be
ruled out to be a surrogate marker of socio-economic con-
dition. This ongoing screening program is valuable as a
surveillance system to monitor HIV-1 and HCV infection
patterns for pregnant women and their offspring over an
extended period of time.
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